The 130% premium to the undisturbed price and the all-cash structure make this a near-certain closing event. The key risk is a competing superior proposal triggering the $13M termination fee, but the 14% locked-up voting support and the premium size make a competing bid unlikely. Monitor for the proxy statement filing and the shareholder vote timeline.
Price Chart
Executive Summary
Silence Therapeutics plc entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, in an all-cash transaction valued at approximately $1.3 billion equity value. Shareholders will receive $20.00 per ADS ($6.6667 per ordinary share), representing a 130% premium to the closing price on October 16, 2026. The transaction is structured as a UK scheme of arrangement, unanimously approved by Silence's board, and is expected to close in Q1 2027, subject to shareholder and regulatory approvals.
Key Financial Metrics
Key Facts
- Acquisition price of $20.00 per ADS ($6.6667 per ordinary share) in cash
- Equity value of approximately $1.3 billion; enterprise value of $1.1 billion
- 130% premium to Silence's closing ADS price on October 16, 2026
- 82% premium to the 30-day VWAP of $10.99
- Transaction structured as a UK scheme of arrangement under Part 26 of the Companies Act 2006
- Unanimously approved by Silence's Board of Directors
- Securityholders holding ~14% of voting power have entered into voting and support agreements
- Expected to close in Q1 2027
- Subject to shareholder approval (75% in value, majority in number), court sanction, HSR, and German antitrust clearance
- No financing condition; Purchaser has committed sufficient funds
- Termination fee of $13 million payable by Silence in certain circumstances
- Divesiran (siRNA candidate for polycythemia vera) is the lead product; has FDA Fast Track and Orphan Drug designations
Financial Impact
Equity value of approximately $1.3 billion; enterprise value of $1.1 billion; all-cash consideration of $20.00 per ADS
Risk Factors
- Shareholder vote requires 75% in value and majority in number approval; failure would terminate the deal
- Regulatory approvals (HSR, German antitrust) could delay or block the transaction
- A competing superior proposal could emerge, though the 130% premium and 14% locked-up support reduce this risk
- Court sanction of the scheme of arrangement is required and could be challenged
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-424702 |
| Document: 0001193125-26-424702-index-headers.html | 0001193125-26-424702 |
| Document: 0001193125-26-424702-index.html | 0001193125-26-424702 |
| Document: 0001193125-26-424702.txt | 0001193125-26-424702 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 9d ago | DEFA14A | $19.61 $19.78 | ▲ +0.87% | ▲ +0.79% | $19.71 (+0.51%) |
Oct 19, 2026 9d ago | DEFA14A | $19.58 $19.78 | ▲ +1.02% | ▲ +1.17% | $19.71 (+0.66%) |
Oct 19, 2026 9d ago | 8-K | $19.58 $19.78 | ▲ +1.02% | ▲ +1.17% | $19.71 (+0.66%) |
Oct 13, 2026 15d ago | SC 13G/A | $8.98 $19.67 | ▲ +119.04% | ▲ +118.59% | $19.71 (+119.49%) |
Oct 13, 2026 15d ago | SC 13G | $8.98 $19.67 | ▲ +119.04% | ▲ +118.59% | $19.71 (+119.49%) |
Aug 10, 2026 11w ago | 424B5 | $14.72 $14.10 | ▲ +4.21% | ▲ +3.81% | $19.71 (−33.90%) |
Aug 10, 2026 11w ago | 8-K | $15.43 $14.35 | ▼ −7.00% | ▼ −6.95% | $19.71 (+27.74%) |
Aug 10, 2026 11w ago | 8-K | $15.43 $14.35 | ▼ −7.00% | ▼ −6.95% | $19.71 (+27.74%) |
Jun 23, 2026 18w ago | 8-K | $9.16 $10.50 | ▲ +14.63% | ▲ +12.92% | $19.71 (+115.17%) |
Mar 5, 2026 33w ago | 8-K | $5.50 $6.97 | ▲ +26.73% | ▲ +28.96% | $19.71 (+258.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers